Phase 2 study, open, of daclatasvir (BMS-790052) and TMC435 in combination with or without ribavirin (RBV), for the treatment of previously untreated subjects or subjects with no response to previous treatment with penginterferon alfa (peglFN) with hepatitis C chronic genotype 1
Bristol-Myers Squibb International Corporation
Pathology and candidate patients
Dr. Moises Diago
Hospital Quirónsalud Valencia.
Direct action anitivirals (ADA) from AbbVie
April 15, 2013
Hospital Quirónsalud Valencia
If you are interested in this clinical trial because you believe that you or a family member of yours can benefit from this new treatment.
You can request a consultation with the cardiology team by sending an email to the address: email@example.com